NASDAQ:DCTH Delcath Systems (DCTH) Stock Price, News & Analysis $14.49 -0.33 (-2.23%) Closing price 11/5/2026 04:00 PM EasternExtended Trading$13.88 -0.62 (-4.24%) As of 05:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Delcath Systems Stock (NASDAQ:DCTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Delcath Systems alerts:Sign Up Key Stats Today's Range$14.24▼$15.2550-Day Range$14.04▼$16.5852-Week Range$8.12▼$17.42Volume554,121 shsAverage Volume305,108 shsMarket Capitalization$502.79 millionP/E Ratio1,450.45Dividend YieldN/APrice Target$26.67Consensus RatingModerate Buy Company Overview Delcath Systems, Inc. is a medical technology company focused on liver-directed cancer treatments. The company develops and commercializes systems designed to deliver high concentrations of chemotherapy to the liver while limiting exposure to the rest of the body. Its primary product in the United States is the HEPZATO KIT, a liver-directed therapy that combines the company’s proprietary hepatic delivery system with melphalan hydrochloride for injection. HEPZATO is approved for the treatment of adult patients with unresectable metastatic uveal melanoma involving the liver, without extrahepatic disease or with limited extrahepatic disease that is not clinically significant. Outside the United States, Delcath markets the corresponding system under the CHEMOSAT brand. The company’s technology is based on percutaneous hepatic perfusion, in which the liver is temporarily isolated from the general circulation so that chemotherapy can be administered directly to the organ and then filtered before the blood returns to the body. Delcath serves hospitals and cancer treatment centers in the United States and selected international markets, including Europe.AI Generated. May Contain Errors. Read More Delcath Systems Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreDCTH MarketRank™: 2.510132396645 of 5 starsDelcath Systems scored higher than 50% of companies evaluated by MarketBeat, and ranked 420th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingDelcath Systems has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialDelcath Systems has a consensus price target of $26.67, representing about 84.0% upside from its current price of $14.49.Amount of Analyst CoverageDelcath Systems has only been the subject of 2 research reports in the past 90 days.Read more about Delcath Systems' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Delcath Systems are expected to grow in the coming year, from ($0.17) to $0.12 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Delcath Systems is 1,450.45, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.92.Price to Earnings Ratio vs. SectorThe P/E ratio of Delcath Systems is 1,450.45, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.45.Price to Book Value per Share RatioDelcath Systems has a P/B Ratio of 4.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Delcath Systems' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.73% of the float of Delcath Systems has been sold short.Short Interest Ratio / Days to CoverDelcath Systems has a short interest ratio ("days to cover") of 6.24.Change versus previous monthShort interest in Delcath Systems has recently decreased by 3.29%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDelcath Systems does not currently pay a dividend.Dividend GrowthDelcath Systems does not have a long track record of dividend growth. News and Social Media2.2 / 5News SentimentN/A News SentimentDelcath Systems has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Delcath Systems this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 2 people have added Delcath Systems to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Delcath Systems insiders have not sold or bought any company stock.Percentage Held by Insiders19.36% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.12% of the stock of Delcath Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Delcath Systems' insider trading history. Receive DCTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DCTH Stock News HeadlinesDelcath Systems: Intriguingly Poised Ahead Of Q3 EarningsNovember 3 at 9:53 PM | seekingalpha.comDelcath Systems to Host Third Quarter 2026 Earnings CallOctober 26, 2026 | businesswire.comMy prediction for December 8thElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout. | Behind the Markets (Ad)Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 11, 2026 | businesswire.comDelcath’s (DCTH) Liver Cancer Device Keeps Growing, But At A CostSeptember 11, 2026 | finance.yahoo.comDelcath Systems Updates Corporate Bylaws and Governance FrameworkAugust 14, 2026 | tipranks.comThese two stocks hit fresh 52-week highs today – DCTH clocks best day in nearly 15 monthsAugust 6, 2026 | msn.comDelcath Systems, Inc. (DCTH) Q2 2026 Earnings Call TranscriptAugust 6, 2026 | seekingalpha.comSee More Headlines DCTH Stock Analysis - Frequently Asked Questions How have DCTH shares performed this year? Delcath Systems' stock was trading at $10.10 on January 1st, 2026. Since then, DCTH stock has increased by 43.5% and is now trading at $14.49. How were Delcath Systems' earnings last quarter? Delcath Systems, Inc. (NASDAQ:DCTH) released its quarterly earnings results on Thursday, August, 6th. The company reported $0.07 earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.16. The firm earned $29.13 million during the quarter, compared to analysts' expectations of $26.25 million. Delcath Systems had a net margin of 0.56% and a trailing twelve-month return on equity of 0.46%. Read the conference call transcript. When did Delcath Systems' stock split? Delcath Systems's stock reverse split on the morning of Tuesday, October 22nd 2019.The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How will Delcath Systems' stock buyback program work? Delcath Systems' board authorized a stock buyback program on Thursday, November 20th 2025, which allows the company to repurchase $25 million in shares, according to EventVestor. This means that the company could buy up to 8.6% of its stock through open market purchases. Stock buyback programs are often an indication that the company's board of directors believes its shares are undervalued. Who are Delcath Systems' major shareholders? Delcath Systems' top institutional shareholders include Simplify Asset Management Inc., Capital Advisors Wealth Management LLC (0.24%), Alps Advisors Inc. (0.13%) and Kopp Family Office LLC (0.08%). Insiders that own company stock include Gil Aharon, Rosalind Advisors, Inc, Gerard J Michel, Vojo Vukovic and Sandra Pennell. View institutional ownership trends. How do I buy shares of Delcath Systems? Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Delcath Systems own? Based on aggregate information from My MarketBeat watchlists, some other companies that Delcath Systems investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Tesla (TSLA), CrowdStrike (CRWD), Advanced Micro Devices (AMD), AppLovin (APP) and Intel (INTC). Company Calendar Last Earnings8/06/2026Today11/05/2026Next Earnings (Estimated)11/09/2026UBS Global Healthcare Conference11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 DCTH's financial health is in the Green zone, according to TradeSmith. DCTH has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:DCTH CIK872912 Webdelcath.com Phone212-489-2100Fax212-489-2102Employees156Year Founded1988Price Target and Rating Average Price Target for Delcath Systems$26.67 High Price Target$32.00 Low Price Target$21.00 Potential Upside/Downside+84.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)$0.01 Trailing P/E Ratio1,450.45 Forward P/E Ratio120.75 P/E GrowthN/ANet Income$2.70 million Net Margins0.56% Pretax Margin1.35% Return on Equity0.46% Return on Assets0.42% Debt Debt-to-Equity RatioN/A Current Ratio9.83 Quick Ratio8.95 Sales & Book Value Annual Sales$95.42 million Price / Sales5.27 Cash Flow$0.05 per share Price / Cash Flow283.50 Book Value$3.15 per share Price / Book4.60Miscellaneous Outstanding Shares34,699,000Free Float27,981,000Market Cap$502.79 million OptionableOptionable Beta0.62 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:DCTH) was last updated on 11/5/2026 by MarketBeat.com Staff. From Our PartnersMy prediction for December 8thElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public co...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the 64 trillion dollar question: is a stock market crash on the way. Weis...Weiss Ratings | SponsoredCritical SpaceX supplier w/ patented tech trading for $5President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredA New Independent “Federal Reserve” Has Just Emerged in AmericaA new independent Federal Reserve has reportedly been created for America. It could be publicly revealed as...Banyan Hill Publishing | SponsoredWrite This Ticker Down NowLarry Benedict went 20 straight years without a losing year. Now he says a major Washington event could trigge...Brownstone Research | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Delcath Systems With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
